Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19969116 | 0.91 | MAPT (0.38) | MEN1NPC1LMNAMAPTRAB9A | |
| SCHEMBL19969110 | 0.91 | MAPT (0.38) | MEN1NPC1LMNAMAPTRAB9A | |
| SCHEMBL19962138 | 0.87 | MAPT (0.40) | MEN1NPC1LMNAMAPTRAB9A | |
| SCHEMBL18180271 | 0.75 | SYK (0.31) | — | |
| SCHEMBL19969198 | 0.75 | SYK (0.31) | — | |
| SCHEMBL18171816 | 0.75 | MAPT (0.43) | MEN1NPC1LMNAMAPTRAB9A | |
| SCHEMBL18180315 | 0.75 | ALDH1A1 (0.39) | MEN1NPC1LMNAMAPTRAB9A | |
| SCHEMBL19962072 | 0.73 | ALDH1A1 (0.32) | NPC1MAPTRAB9A | |
| SCHEMBL19962156 | 0.72 | PSMB5 (0.35) | MEN1KMT2A | |
| SCHEMBL19969154 | 0.72 | PSMB5 (0.35) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2H, POLR2E | MEN1 4064/4885NPC1 273/4885LMNA 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.